| Name | Title | Contact Details |
|---|
HealthLinc services include primary and preventive care services; health and wellness education; chronic disease management; prenatal care; women`s health services; men`s health services; wellness checks and immunizations; services to treat depression, anxiety, and many other behavioral health conditions and disorders; comprehensive dental services; pharmacy services and optometry services.
GreenPrint, a global environmental technology company, offers sustainability as a service with patent-protected programs that deliver environmental impact and bottom-line results. An Inc. 5000 company and a member of 1% Percent for the Planet, GreenPrint`s turnkey offerings help companies meet sustainability goals while increasing brand value and customer loyalty – making it easy for businesses to do well by doing good. GreenPrint, A Public Benefit Corporation, is on pace to offset over 30 million metric tons of carbon by 2025.
We are a leading developer and provider of innovative wearable technologies used by our customers to make products for consumers, military, and industry. Kopin is a leading developer and provider of technologies and solutions that enhance the visual, verbal, audio, and head-gesture command capabilities of wearable headset products. Innovation is in our DNA.
Integrated Test is a Gilbert, AZ-based company in the Computers and Electronics sector.
Xceleron believes that AMS technology and our expertise can get life-changing products (drugs and biobased) quickly and cost-effectively to people who need them. We work with integrity and an open mind and are driven by science and the spirit of collaboration. Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials. Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.